We hold the technology to make individualized oncology therapies a reality
TCXpress™ and NEOXpress™, working together, can match T-cell receptors (TCRs) with their targets, and within the context of certain patients, discover TCRs against tumor-specific antigens (neoantigens).
These technologies hold the power to unlock the potential of T-cell therapy for the treatment of cancer.
TCXpress™
A proprietary high-throughput and efficient TCR search and capture platform, TCXpress™ is capable of processing thousands of single T cells directly into functionally expressed TCRs within a matter of days, thereby creating extensive libraries without the need for lengthy predictive sequencing.
TCXpress™
Isolate T cells
Single Cell Sorting
and Amplification
Cloning and
Plasmid Expression
TCR
Repertoire Library
Screen
and Select
TCRs Selected for
Adoptive Cell Therapy
Isolate T cells
Single Cell Sorting
and Amplification
Cloning and
Plasmid Expression
TCR
Repertoire Library
Screen
and Select
TCRs Selected for
Adoptive Cell Therapy
NEOXpress™
A proprietary patient-specific neoantigen discovery platform, NEOXpress™ screens tumor-resident TCRs for reactivity to identified neoantigens. In this bottom-up approach, together with T-cell reporter libraries created from TCXpress™, NEOXpress™ provides the opportunity to rapidly screen and test the function of thousands of TCRs to find those specific to key neoantigens in a multiplexed way.
TCXpress™
TCXpress™ is a ground-breaking platform that can generate libraries containing 1000’s of intact TCRs in a testable format in about 1 week.
NeoXpress™
NEOXpress™ is a predictive platform that relies on proprietary bioinformatics to create libraries containing up to 100s of neoantigens per tumor sample.
Tumor Sample
NeoXpress™
TcXpress™
TCRs Selected for Adoptive
Cell Therapy
TCXpress™
TCXpress™ is a ground-breaking platform that can generate libraries containing 1000’s of intact TCRs in a testable format in about 1 week.
NeoXpress™
NEOXpress™ is a predictive platform that relies on proprietary bioinformatics to create libraries containing up to 100s of neoantigens per tumor sample.
Excited by our technology? Contact us, we’d love to tell you more.
